此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study on Prostate Salvage Using High-dose-rate Brachytherapy (PROSCATE)

Multicenter Prospective Observational Study on Prostate Salvage Using High-dose-rate Brachytherapy

A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and magnetic resonance imaging (MRI)) and positive biopsy-using two fractions of high-dose-rate (HDR) brachytherapy.

研究概览

详细说明

The objectives of this prospective, multicenter study are:

  • Primary:

    1. Biochemical relapse-free survival, defined as the time to biochemical relapse (nadir plus 2 ng/mL - Phoenix criteria).

  • Secondary:

    1. Local relapse-free survival, defined as the time from treatment to local relapse confirmed by imaging (choline PET/MRI).
    2. Analysis of acute and chronic toxicity (Common Terminology Criteria for Adverse Events [CTCAE] version 5).
    3. Assessment of patient quality of life before and after treatment to analyze the impact of local re-irradiation on daily life using the following questionnaires: International Prostate Symptom Score (IPSS), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Prostate Module (EORTC QLQ-PR25).

Primary outcome measure: Biochemical relapse-free survival, and analysis of toxicity and quality of life in patients treated with salvage brachytherapy following radical treatment.

Study population, total number of subjects, and duration: Patients who received radical-intent radiotherapy as their initial treatment (brachytherapy alone, external beam radiotherapy, or external beam radiotherapy plus a brachytherapy boost) and were diagnosed with local recurrence via next-generation imaging techniques (choline PET/PSMA PET) and prior biopsy; these patients are scheduled to undergo salvage brachytherapy as part of routine clinical practice. A calculated sample size of 63 patients will be reached over a 2-year recruitment period. Follow-up will be conducted according to standard clinical practice every 6 months for the 4-year duration of the study.

研究类型

观察性的

注册 (估计的)

63

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Alicante
      • Benidorm、Alicante、西班牙、03501
        • 招聘中
        • Hospital HCB Benidorm
        • 接触:
        • 首席研究员:
          • Silvia Rodríguez Villalba, MD
    • Barcelona
      • L'Hospitalet de Llobregat、Barcelona、西班牙、08908
        • 招聘中
        • Instituto Catalán de Oncología L'Hospitalet
        • 接触:
        • 首席研究员:
          • Andrea Slocker Escarpa, MD
    • Cantabria
      • Santander、Cantabria、西班牙、39008
        • 招聘中
        • Hospital Universitario Marqués de Valdecilla
        • 接触:
        • 首席研究员:
          • Ana Soledad García Blanco, MD
    • Córdoba
      • Córdoba、Córdoba、西班牙、14004
    • Guipuzcoa
      • San Sebastián、Guipuzcoa、西班牙、20014
        • 尚未招聘
        • Instituto Oncológico de San Sebastián (Onkologikoa)
        • 接触:
        • 首席研究员:
          • Alai Goñi Ramírez, MD
    • Madrid
      • Madrid、Madrid、西班牙、28034
        • 招聘中
        • Hospital Universitario Ramón y Cajal
        • 接触:
        • 首席研究员:
          • María Teresa Muñoz Migueláñez, MD
    • Navarre
      • Pamplona、Navarre、西班牙、31008
        • 招聘中
        • Hospital Universitario de Navarra
        • 接触:
        • 首席研究员:
          • Ignacio Visus Fernández de Manzano, MD
    • Pontevedra
      • Vigo、Pontevedra、西班牙、36312
        • 招聘中
        • Hospital Meixoeiro
        • 接触:
        • 首席研究员:
          • Patricia Willisch Santamaría, MD
    • Valencia
      • Valencia、Valencia、西班牙、46026
        • 招聘中
        • Hospital Universitario y Politécnico La Fe
        • 接触:
          • Francisco Javier Celada Álvarez, MD
          • 电话号码:961 24 40 00
          • 邮箱:celada_fra@gva.es
        • 首席研究员:
          • Francisco Javier Celada Álvarez, MD
    • Vizcaya
      • Barakaldo、Vizcaya、西班牙、48903
        • 尚未招聘
        • Hospital Universitario de Cruces
        • 接触:
        • 首席研究员:
          • David Büchser García, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Patients treated with radical-intent radiotherapy as their primary treatment (brachytherapy alone, external beam radiotherapy, or external beam radiotherapy plus a brachytherapy boost) who have been diagnosed with local recurrence via next-generation imaging techniques (Choline PET or PSMA PET) and prior biopsy, and who are to undergo salvage brachytherapy as part of routine clinical practice.

描述

Inclusion Criteria:

  • Age over 18 years.
  • Patients diagnosed with local recurrence confirmed by next-generation imaging and a positive biopsy.
  • Hormone-sensitive patient.
  • Patients whose initial treatment consisted of brachytherapy alone, external beam radiotherapy, or external beam radiotherapy with a prostate brachytherapy boost.

Exclusion Criteria:

  • Metastatic disease.
  • Castration-resistant prostate cancer, defined according to EAU (European Association of Urology) guidelines: A patient who progresses despite maintaining testosterone levels within the castration range (testosterone <50 ng/dL or <1.7 nmol/L) and presents with at least one of the following factors: Three consecutive rises in PSA (Prostate-Specific Antigen) levels, measured one week apart, representing two increases of 50% above the nadir, with a PSA level >2; PSA progression despite successive hormonal manipulations; Progression of bone lesions: progression or appearance of two or more bone lesions, or soft-tissue progression according to Response Evaluation Criteria in Solid Tumors (RECIST criteria).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Biochemical relapse-free survival
大体时间:From the date of salvage brachytherapy to 48 months after treatment

Time from salvage brachytherapy to biochemical recurrence of prostate cancer, defined according to the Phoenix definition as a rise in prostate-specific antigen (PSA) of ≥2 ng/mL above the post-treatment PSA nadir. Patients without biochemical recurrence will be censored at the date of their last available PSA assessment or at the end of the study follow-up. PSA measurements will be obtained at 1 month after treatment and subsequently every 6 months through 48 months.

From the date of salvage brachytherapy to 48 months after treatment

次要结果测量

结果测量
措施说明
大体时间
Baseline Characteristics
大体时间:Baseline, Day 0

Initial disease characteristics: Initial PSA, Gleason/Grade Group, Stage Biopsy characteristics, Initial imaging, Initial treatment.

Disease characteristics at recurrence: PSA at recurrence, prostate-specific antigen doubling time (PSADT), Location of recurrence, Recurrence biopsy, Urinary symptoms, Imaging findings

Baseline, Day 0
Incidence of Late and Chronic Treatment-Related Toxicity
大体时间:From 1 month after salvage brachytherapy to 48 months after treatment

Incidence and severity of late and chronic treatment-related toxicity following salvage brachytherapy, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Toxicities will include genitourinary and gastrointestinal toxicities and other treatment-related adverse events identified during follow-up.

From 1 month after salvage brachytherapy to 48 months after treatment
Local Relapse-Free Survival
大体时间:From the date of salvage brachytherapy to 48 months after treatment

Time from salvage brachytherapy to radiologically confirmed local recurrence of prostate cancer. Local recurrence will be assessed using imaging techniques, including prostate MRI, choline PET, and/or PSMA PET, according to routine clinical practice. Patients without radiologically confirmed local recurrence will be censored at the date of their last available imaging assessment or at the end of the study follow-up.

From the date of salvage brachytherapy to 48 months after treatment
Incidence of Acute Treatment-Related Toxicity
大体时间:From the date of salvage brachytherapy to 1 month after treatment

Incidence and severity of acute treatment-related toxicity following salvage brachytherapy, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Acute toxicity will include genitourinary and gastrointestinal toxicities and other treatment-related adverse events occurring during the acute post-treatment period.

From the date of salvage brachytherapy to 1 month after treatment
Change in International Prostate Symptom Score (IPSS) From Baseline
大体时间:Baseline and every 6 months after salvage brachytherapy through 48 months

Change in urinary symptoms assessed using the International Prostate Symptom Score (IPSS). The IPSS will be assessed before salvage brachytherapy and during follow-up every 6 months. The change from baseline will be evaluated over the study follow-up period.

Baseline and every 6 months after salvage brachytherapy through 48 months
Change in Prostate Cancer-Specific Quality of Life (FACT-P) From Baseline
大体时间:Baseline and every 6 months after salvage brachytherapy through 48 months

Change in health-related quality of life assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. The FACT-P is a 39-item questionnaire assessing health-related quality of life in patients with prostate cancer. The total score ranges from 0 to 156, with higher scores indicating better health-related quality of life. The questionnaire will be administered before salvage brachytherapy and during follow-up every 6 months. Changes from baseline in the FACT-P total score will be evaluated throughout the study follow-up period.

Baseline and every 6 months after salvage brachytherapy through 48 months
Change in Prostate Cancer-Specific Quality of Life (EORTC QLQ-PR25) From Baseline
大体时间:Baseline and every 6 months after salvage brachytherapy through 48 months

Change in prostate cancer-specific health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Prostate Module (EORTC QLQ-PR25). The EORTC QLQ-PR25 consists of 25 items scored on a 0 to 100 scale after linear transformation. Higher scores indicate greater symptom burden for symptom scales and higher levels of functioning or activity for the sexual activity/function scales. The questionnaire will be administered before salvage brachytherapy and during follow-up every 6 months. Changes from baseline in the EORTC QLQ-PR25 scores will be evaluated throughout the study follow-up period..

Baseline and every 6 months after salvage brachytherapy through 48 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Patricia Willisch Santamaría, MD PhD、Galicia Sur Health Research Institute
  • 学习椅:Pablo Raña Díez、Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月11日

初级完成 (估计的)

2032年1月31日

研究完成 (估计的)

2032年4月30日

研究注册日期

首次提交

2026年9月30日

首先提交符合 QC 标准的

2026年9月30日

首次发布 (实际的)

2026年10月6日

研究记录更新

最后更新发布 (实际的)

2026年10月9日

上次提交的符合 QC 标准的更新

2026年10月6日

最后验证

2026年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅